XTL 6865

N/A

Report date: 2022/09/02 16:41:48

Base Information

Drug NameXTL 6865
Drug Alias NameAnti-HCV dual monoclonal antibody-XTL BiopharmaceuticalsHepeX-CXTL-6865XTL-002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionHepatitis C virus replication inhibitorsAnti-E2
TargetsHepatitis C virus E2 glycoprotein
Therapy Area/IndicationsHepatitis C
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIsrael
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesXtl Biopharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesInotek Pharmaceuticals CorporationB&C PharmaXtl Biopharmaceuticals
Active IndicationsN/A
Inactive IndicationsHepatitis C

Other Information

ATC CodeN/A
Related LinksN/A